Authors
Latest:
Starting at the Front Line in Metastatic Pancreatic Cancer As New Options Emerge, How Do You Select and Sequence?Experts in gastrointestinal cancer focus on frontline therapy options for patients with pancreatic cancer.
Latest:
Unmet Needs and the Future of Kidney CancerDrs Tom Powles and Brian Shimkus muse on the unmet needs of kidney cancers and treatments on the horizon to look forward to.
Latest:
Relacorilant May Be ‘Synergistic’ With Nab-Paclitaxel in Ovarian CancerInvestigators of a phase 2 study suggest that relacorilant may add to a ‘sparse’ field of effective treatment options for patients with platinum-resistant or refractory ovarian cancer.
Latest:
The Effect of Prior Cancer on Survival of Patients With ThymomaShilong Wu, MD, and co-authors discuss how patients with thymoma are affected by prior cancer history.
Latest:
Unmet Needs and Future Directions in the Management of Multiple MyelomaExperts from Ochsner Health close out their panel on multiple myeloma management by identifying unmet needs and sharing excitement for future evolution in the treatment landscape.
Latest:
Expanding Genetic Testing in Oncology Through Specified CharacteristicsPatients with breast cancer or those who are survivors can be candidates for genetic testing, according to Brittany L. Bychkovsky, MD, MSc.
Latest:
Utility of the 21-Gene Recurrence Score in Node-Positive Breast CancerABSTRACT The 21-gene Recurrence Score (RS) assay has been validated as both a prognostic and predictive tool in node-negative (pN0), estrogen receptor–positive (ER+), HER2-negative (HER2–) breast cancer. A large body of evidence supports the clinical utility of the RS in the node positive (pN+) population as well. Retrospective analyses of archived tissue from multiple clinical trials have found the RS to be prognostic in both endocrine therapy (ET)-treated and chemotherapy-treated patients with pN+ disease. Distribution of RS results in pN+ patients have also been consistent with those of pN0 populations. Data from the SWOG 8814 trial and large population-based registries further support the prognostic and potential predictive value of the RS. Specifically, patients with 1 to 3 positive nodes and RS less than 18 derived negligible benefit from adjuvant chemotherapy in these studies. In the prospective West German Study Group PlanB and ADAPT trials, pN+ patients with RS less than 11 and RS ≤25, respectively, who were treated with ET alone experienced excellent outcomes. Finally, 5-year results of the RxPONDER clinical trial randomizing patients with 1 to 3 positive nodes and RS ≤25 to ET alone vs ET plus chemotherapy confirmed an absence of chemotherapy benefit in postmenopausal patients. Clinical practice guidelines support use of the RS in the pN+, ER+/HER2– population, and many institutions have adopted the RS to guide clinical decision-making, resulting in a net reduction of adjuvant chemotherapy use. This review highlights the existing data supporting the prognostic and predictive ability of the RS in pN+ disease, current practice patterns related to RS use in this population, and emerging applications.
Latest:
Which Treatment for Which Patient: Rectal Cancer Management After PROSPECT TrialDetermining treatment options for patients with locally advanced rectal cancer after the PROSPECT trial data readout adds an important level to the decision-making process.
Latest:
Face-Off: Award Presentation CeremonyFollowing a spirited debate, Joshua K. Sabari, MD, presents the winning team with the coveted title of victors of this CancerNetwork® Face-Off event.
Latest:
Assessing the Benefit of CAR T-cell Therapies for mCRPCA phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Latest:
Adam J. Gadzinski, MD, MS, on Up-and-Coming Research for Urologic OncologyThe expert in urologic oncology spoke about new innovations that he believes will aid in treating patients with urologic cancers.
Latest:
Managing Hematological Toxicities Associated with Bispecifics in MMExperts on multiple myeloma provide insights on the management of hematological toxicities associated with bispecific antibodies.
Latest:
Investigating the Use of Circulating Tumor DNA in Early-Stage Colon CancerArdaman Shergill, MD, and Aparna Raj Parikh, MD, explore ongoing clinical investigations evaluating the use of circulating tumor DNA in the treatment of early-stage colon cancer.
Latest:
The Effect of Prior Cancer on Survival of Patients With ThymomaShilong Wu, MD, and co-authors discuss how patients with thymoma are affected by prior cancer history.
Latest:
Building On Outcomes With Isatuximab in Newly Diagnosed MyelomaNext steps for research in the multiple myeloma space may include the development of novel CAR T-cell strategies and bispecific antibodies.
Latest:
Pediatric Locally Advanced Synovial Sarcoma: What Would Be the Best Treatment Option?KEY POINTS • Synovial sarcomas are often mistreated with unplanned tumor resection. • Attention from specialists early in the course of SS can minimize the risk of recurrence, metastases, and the necessity for resurgery, all of which are increased with unplanned tumor resection. • Chemotherapy alone does not provide sufficient local control of the tumor. • Resurgery, in conjunction with radiotherapy and chemotherapy, is the best choice of management for this patient.
Latest:
Using a Whole-Person Approach in Supportive Care to Improve Cancer OutcomesThe Together for Supportive Cancer Care coalition may advance the national conversation in ensuring comprehensive care for all patients with cancer.
Latest:
De-Escalation Treatment for Human Papillomavirus–Related Oropharyngeal Cancer: Questions for Practical ConsiderationHow treatment paradigms regarding HPV-positive squamous cell carcinoma will evolve, particularly in the era of precision medicine, is a provocative question and is the subject of this review.
Latest:
Oncology Peer Review On-The-Go: Integrative Oncology in Young Population with Breast CancerYancey Warren, Jr, MD, MAT, and Lejla Hadzikadic-Gusic, MD, MSc, spoke with CancerNetwork® about their work investigating the use of integrative oncology services among young patients diagnosed with breast cancer.
